Copyright
©The Author(s) 2021.
World J Gastroenterol. Mar 7, 2021; 27(9): 760-781
Published online Mar 7, 2021. doi: 10.3748/wjg.v27.i9.760
Published online Mar 7, 2021. doi: 10.3748/wjg.v27.i9.760
Ref. | Number of patients | Antibiotics group | Control group | Primary outcome | Conclusions |
AVOD[86] | 623 | At least 10 d of Abx, IV initially, then PO after admission or upon discharge | IV fluids | Complications, length of stay, need for surgery | Complications: 1% in Abx arm, 1.9% in control group (P = 0.302). LOS: 3 d in both groups. Recurrent diverticulitis/readmission in 1 year: 16% in both groups (P = 0.881) |
DIABOLO[63] | 528 | 10 d course of Abx, IV for 2 d, then PO | Observation as outpatient if clinical criteria satisfied | Time to recovery | Median time (d) to recovery: Observation 14 (IQR 6-35); antibiotic 12 (7-30; HR 0.91; P = 0.151) |
- Citation: Hanna MH, Kaiser AM. Update on the management of sigmoid diverticulitis. World J Gastroenterol 2021; 27(9): 760-781
- URL: https://www.wjgnet.com/1007-9327/full/v27/i9/760.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i9.760